Clinical trialPhase 1 / Phase 2Recruiting
Evaluation of XYA02 in Patients With Advanced Solid Tumors
A Phase 1b/2, Multicenter, Non-randomized, Open-label, Multiple Dose First- In-Human Study of XYA02 in Patients With Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 17 September 2026
- Expected end
- 15 September 2030
- Enrollment
- 190 participants
- Sites
- 5
- Primary outcomes
- Frequency of Treatment Emergent Adverse Events of XYA02; Duration of Treatment Emergent Adverse Events of XYA02; Severity of Treatment Emergent Adverse Events of XYA02; Determine the Maximum Tolerated Dose (MTD) of XYA02
- Sponsor
- Industry
- Results posted
- No
- Last update
- 25 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try